Stocktoria
AETHLON MEDICAL INC AEMD
AETHLON MEDICAL INC (AEMD) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| AEMD | AETHLON MEDICAL INC | 3/9 | — | — | — |
| MDLN | Medline Inc. | 6/9 | 2.84 | 44.1 | +11.5% |
| SYK | STRYKER CORP | 4/9 | 3.96 | 39.3 | +11.2% |
| MMM | 3M CO | 5/9 | 5.46 | 26.3 | +1.5% |
| BDX | BECTON DICKINSON & CO | 6/9 | 2.29 | 25.6 | +8.2% |
| BSX | BOSTON SCIENTIFIC CORP | 4/9 | 2.81 | — | +19.9% |
| BAX | BAXTER INTERNATIONAL INC | 5/9 | 3.86 | — | +5.7% |
About AETHLON MEDICAL INC
Aethlon Medical, Inc., a medical therapeutic company, engages in developing novel immunotherapeutic devices in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation, and other disease states. The company was founded in 1984 and is based in San Diego, California.
FAQ
Is AEMD financially healthy?
AETHLON MEDICAL INC's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does AEMD pay a dividend?
No, AETHLON MEDICAL INC does not currently pay a dividend.
How profitable is AEMD?
In FY2026, AETHLON MEDICAL INC had a return on equity of -146.4%.
What is the analyst price target for AEMD?
The average Wall-Street price target for AETHLON MEDICAL INC is $3.25, about 6.9% above the recent price, from 2 analysts.
Is AEMD a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on AETHLON MEDICAL INC: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2026-03-31. Facts plus Stocktoria's own computed scores — not investment advice.